keyword
MENU ▼
Read by QxMD icon Read
search

Prostate Cancer Focal Therapy

keyword
https://www.readbyqxmd.com/read/29439879/can-focal-therapy-replace-radical-therapy-for-prostate-cancer-against-focal-therapy
#1
Chad Reichard, Brian Francis Chapin
Until prospective data demonstrate the oncologic efficacy of focal therapy for clinically significant, localized prostate cancer, it should be considered as experimental and only performed within the confines of a clinical trial.
February 10, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29432339/18f-choline-pet-mr-can-detect-and-delineate-local-recurrence-after-high-intensity-focused-ultrasound-therapy-of-prostate-cancer
#2
Irene A Burger, Andrei Gafita, Julian Müller, Benedikt Kranzbühler, Olivio F Donati, Daniel Eberli
Restaging local recurrence after high-intensity focused ultra-sound (HIFU) is based on multiparametric MRI (mpMRI). However, postinterventional changes of the tissue, such as edema or hemorrhage, are limiting tumor detection on mpMRI. We present a case of a rising prostate-specific antigen values, negative mpMRI, and a Gleason score of 4+4 on template biopsy after HIFU. On F-choline PET/MR, high focal uptake was detected at the location of positive biopsy. Re-HIFU based on the fused F-choline PET/MR images was performed, followed by a recurrence-free period of 11 months...
February 9, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29420984/mr-imaging-guided-focal-treatment-of-prostate-cancer-an-update
#3
REVIEW
Sherif G Nour
Focal treatment of prostate cancer has evolved from a concept to a practice in the recent few years and is projected to fill an existing need, bridging the gap between conservative and radical traditional treatment options. With its low morbidity and rapid recovery time compared with whole-gland treatment alternatives, focal therapy is poised to gain more acceptance among patients and health care providers. As our experience with focal treatment matures and evidence continues to accrue, the landscape of this practice might look quite different in the future...
March 2018: Radiologic Clinics of North America
https://www.readbyqxmd.com/read/29420981/prostate-mr-imaging-for-posttreatment-evaluation-and-recurrence
#4
REVIEW
Sonia Gaur, Baris Turkbey
Prostate multiparametric MR imaging (mpMRI) plays an important role in local evaluation after treatment of prostate cancer. After radical prostatectomy, radiation therapy, and focal therapy, mpMRI can be used to visualize normal post-treatment changes and to diagnose locally recurrent disease. An understanding of the various treatments and expected changes is essential for complete and accurate post-treatment mpMRI interpretation.
March 2018: Radiologic Clinics of North America
https://www.readbyqxmd.com/read/29373215/focal-therapy-in-primary-localised-prostate-cancer-the-european-association-of-urology-position-in-2018
#5
Henk G van der Poel, Roderick C N van den Bergh, Erik Briers, Philip Cornford, Alex Govorov, Ann M Henry, Thomas B Lam, Malcolm D Mason, Olivier Rouvière, Maria De Santis, Peter-Paul M Willemse, Hendrik van Poppel, Nicolas Mottet
Radical treatment of localised prostate cancer is recognised to be an unnecessary intervention or overtreatment in many men. Consequently, there has been a rapid uptake in the use of focal ablative therapies. However, there are several biological and practical concerns about such approaches as they have yet to be proved as robust treatment options. In particular, the multifocal nature of prostate cancer argues against unifocal treatment, while limitations in imaging can preclude the accurate identification of the number, location, and extent of prostate cancer foci...
January 17, 2018: European Urology
https://www.readbyqxmd.com/read/29373089/multiparametric-mr-imaging-of-the-prostate-after-treatment-of-prostate-cancer
#6
Pritesh Patel, Melvy S Mathew, Igor Trilisky, Aytekin Oto
The use of multiparametric magnetic resonance (MR) imaging in prostate cancer therapy is increasing, as newer treatment methods and management approaches emerge. The mainstays of therapy-radiation and surgery-are being supplemented (and even replaced) by novel focal therapy methods. Laser and ultrasonographic ablation, photodynamic therapy, electroporation, and cryoablation are the most common focal therapies, each with its own imaging findings. Typical ablation zones have a central focus of enhancement with peripheral rim enhancement; thus, dynamic contrast material-enhanced (DCE) MR imaging is the most important sequence for evaluation of treatment in the immediate posttherapeutic setting...
January 26, 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29336835/standard-whole-prostate-gland-radiotherapy-with-and-without-lesion-boost-in-prostate-cancer-toxicity-in-the-flame-randomized-controlled-trial
#7
Evelyn M Monninkhof, Juliette W L van Loon, Marco van Vulpen, Linda G W Kerkmeijer, Floris J Pos, Karin Haustermans, Laura van den Bergh, Sofie Isebaert, Gill M McColl, Robert Jan Smeenk, Juus Noteboom, Iris Walraven, Petra H M Peeters, Uulke A van der Heide
PURPOSE: To compare toxicity rates in patients with localized prostate cancer treated with standard fractionated external beam radiotherapy (EBRT) with or without an additional integrated boost to the macroscopically visible tumour. MATERIAL AND METHODS: FLAME is a phase 3 multicentre RCT (NCT01168479) of patients with pathologically confirmed localized intermediate or high-risk prostate cancer. The standard treatment arm (n = 287) received a dose to the entire prostate of 77 Gy in 35 fractions...
January 11, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29315174/oligorecurrent-nodal-prostate-cancer-long-term-results-of-an-elective-nodal-irradiation-approach
#8
Sebastien Tran, Sandra Jorcano, Teresa Falco, Giorgio Lamanna, Raymond Miralbell, Thomas Zilli
OBJECTIVES: The objective of this study was to report long-term results of elective nodal radiotherapy (ENRT) in prostate cancer (PCa) patients with oligorecurrent nodal disease after primary treatment. METHODS: Data of 53 oligorecurrent PCa patients (N1 and/or M1a) with ≤5 nodal metastases (n=108) treated with ENRT combined with androgen deprivation therapy (ADT) between 2004 and 2016 were retrospectively reviewed. Median prostate-specific antigen (PSA) and PSA doubling time (DT) were 3...
January 8, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29314097/effect-of-fak-inhibitor-vs-6063-defactinib-on-docetaxel-efficacy-in-prostate-cancer
#9
Hui-Ming Lin, Brian Y Lee, Lesley Castillo, Calan Spielman, Judith Grogan, Nicole K Yeung, James G Kench, Phillip D Stricker, Anne-Maree Haynes, Margaret M Centenera, Lisa M Butler, S Martin Shreeve, Lisa G Horvath, Roger J Daly
BACKGROUND: Docetaxel, the standard chemotherapy for metastatic castration-resistant prostate cancer (CRPC) also enhances the survival of patients with metastatic castration-sensitive prostate cancer (CSPC) when combined with androgen-deprivation therapy. Focal Adhesion Kinase (FAK) activation is a mediator of docetaxel resistance in prostate cancer cells. The aim of this study was to investigate the effect of the second generation FAK inhibitor VS-6063 on docetaxel efficacy in pre-clinical CRPC and CSPC models...
January 5, 2018: Prostate
https://www.readbyqxmd.com/read/29300208/review-of-optimal-techniques-for-robotic-assisted-radical-prostatectomy
#10
Khushabu Kasabwala, Neal A Patel, Jim C Hu
PURPOSE OF REVIEW: Robotic-assisted radical prostatectomy has been rapidly adopted and is now the standard of care in the surgical management of prostate cancer. Since the initial description in 2001, the technique has evolved to optimize oncological functional outcomes. Herein, we review key techniques for the robotic-assisted radical prostatectomy. RECENT FINDINGS: With the current influx of new technology such as focal therapy, stereotactic body radiation therapy and prostate-sparing treatments, there is greater emphasis on maximizing outcomes of robotic-assisted radical prostatectomy...
January 2, 2018: Current Opinion in Urology
https://www.readbyqxmd.com/read/29277585/a-comparison-of-time-taken-to-return-to-baseline-erectile-function-following-focal-and-whole-gland-ablative-therapies-for-localized-prostate-cancer-a-systematic-review
#11
REVIEW
Nicholas A Faure Walker, Joseph M Norris, Taimur T Shah, Tet Yap, Paul Cathcart, Caroline M Moore, Hashim U Ahmed, Mark Emberton, Suks Minhas
OBJECTIVES: To systematically review erectile function (EF) outcomes following primary whole gland (WG) and focal ablative therapies for localized prostate cancer to ascertain whether the treatment modality or intended treatment volume affects the time taken to recover baseline EF. METHOD AND MATERIALS: A systematic review was performed according to the preferred reporting items for systematic review and meta-analysis statement. Inclusion criteria were men with localized prostate cancer treated with primary, ablative therapy...
February 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29245927/a-bioinformatics-to-clinic-sequential-approach-to-analysis-of-prostate-cancer-biomarkers-using-tcga-datasets-and-clinical-samples-a-new-method-for-precision-oncology
#12
Hidekazu Yoshie, Anna S Sedukhina, Kimino Minagawa, Keiko Oda, Shigeko Ohnuma, Nobuyuki Yanagisawa, Ichiro Maeda, Masayuki Takagi, Hiroya Kudo, Ryuto Nakazawa, Hideo Sasaki, Toshio Kumai, Tatsuya Chikaraishi, Ko Sato
Biomarker-driven cancer therapy has met with significant clinical success. Identification of a biomarker implicated in a malignant phenotype and linked to poor clinical outcome is required if we are to develop these types of therapies. A subset of prostate adenocarcinoma (PACa) cases are treatment-resistant, making them an attractive target for such an approach. To identify target molecules implicated in shorter survival of patients with PACa, we established a bioinformatics-to-clinic sequential analysis approach, beginning with 2-step in silico analysis of a TCGA dataset for localized PACa...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29232270/novel-focal-therapy-treatment-options-for-prostate-cancer
#13
Ryan P Werntz, Scott E Eggener
PURPOSE OF REVIEW: Examine and discuss novel focal therapy treatment options for prostate cancer. RECENT FINDINGS: With the widespread adoption of mpMRI-guided biopsies for prostate cancer, use of image-guided treatment of prostate cancer has increased. Focal therapies leading to partial gland ablation such as partial prostatectomy, focal laser ablation, irreversible electroporation, vascular targeted photodynamic therapy, and focal radiofrequency ablation have emerged and begun to be properly evaluated...
December 9, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29232269/mr-guided-biopsy-and-focal-therapy-new-options-for-prostate-cancer-management
#14
Fuad F Elkhoury, Demetrios N Simopoulos, Leonard S Marks
PURPOSE OF REVIEW: Options for prostate cancer management are rapidly expanding. The recent advent of MRI technology has led to guided prostate biopsies by radiologists working in-bore or by urologists using MR/US fusion technology. The resulting tumor visualization now provides the option of focal therapy. Currently available are highly directed energies - focused ultrasound (HIFU), cryotherapy, and laser - all offering the hope of curing prostate cancer with few side effects. RECENT FINDINGS: MRI now enables visualization of many prostate cancers...
December 11, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29208480/robotic-stereotactic-retreatment-for-biochemical-control-in-previously-irradiated-patients-affected-by-recurrent-prostate-cancer
#15
M Loi, V Di Cataldo, G Simontacchi, B Detti, P Bonomo, L Masi, I Desideri, D Greto, G Francolini, V Carfora, D Pezzulla, M Perna, G A Carta, L Livi
AIMS: Robotic stereotactic body radiotherapy (rSBRT) to local recurrences emerged as a valuable option for exclusive local failure after prior external beam radiation therapy (EBRT) for localised prostate cancer. The aim of this study was to assess the efficacy and safety of rSBRT in patients experiencing locally recurrent prostate cancer after prior definitive or postoperative radiotherapy using the Cyberknife. MATERIALS AND METHODS: Data from 50 patients were retrospectively reviewed...
December 2, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29206373/focal-therapy-will-be-the-next-step-on-prostate-cancer-management-opinion-no
#16
EDITORIAL
Wagner Eduardo Matheus, Ubirajara Ferreira
No abstract text is available yet for this article.
November 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29206372/focal-therapy-will-be-the-next-step-on-prostate-cancer-management-opinion-yes
#17
EDITORIAL
Stênio de Cássio Zequi
No abstract text is available yet for this article.
November 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29174615/can-focal-treatment-replace-radical-treatment-in-prostate-cancer-for-focal-therapy
#18
Scott Eggener
No abstract text is available yet for this article.
November 22, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29163793/rapid-ultra-low-coverage-copy-number-profiling-of-cell-free-dna-as-a-precision-oncology-screening-strategy
#19
Daniel H Hovelson, Chia-Jen Liu, Yugang Wang, Qing Kang, James Henderson, Amy Gursky, Scott Brockman, Nithya Ramnath, John C Krauss, Moshe Talpaz, Malathi Kandarpa, Rashmi Chugh, Missy Tuck, Kirk Herman, Catherine S Grasso, Michael J Quist, Felix Y Feng, Christine Haakenson, John Langmore, Emmanuel Kamberov, Tim Tesmer, Hatim Husain, Robert J Lonigro, Dan Robinson, David C Smith, Ajjai S Alva, Maha H Hussain, Arul M Chinnaiyan, Muneesh Tewari, Ryan E Mills, Todd M Morgan, Scott A Tomlins
Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We sought to demonstrate the utility of a pan-cancer, rapid, inexpensive, whole genome NGS of cfDNA approach (PRINCe) as a precision oncology screening strategy via ultra-low coverage (~0.01x) tumor content determination through genome-wide copy number alteration (CNA) profiling...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29122512/-salvage-prostate-brachytherapy-a-solution-for-local-failures-after-a-primary-radiation-therapy
#20
J-M Cosset, G Créhange
Salvage brachytherapy after a first prostate radiation therapy is an emerging technique, which has to be considered in the therapeutic armamentarium in the clinically challenging context of patients with isolated local failure from prostate cancer who may still be considered for cure. These occult failures are more and more frequently diagnosed at an early stage, thanks to targeted biopsies and advances in imaging modalities, such as multiparametric MRI and PET-CT. Salvage brachytherapy benefits from the implantation accuracy of brachytherapy procedures using 3D dosimetry and has resulted in more than 50% tumour control rates with long-term...
November 6, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
keyword
keyword
110778
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"